Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 11Neoplasms 4Stomach Neoplasms 3Rare Malignant Neoplasm 3Esophageal Neoplasms 3Colorectal Neoplasms 3Skin Diseases 2Pancreatic Neoplasms 2Obesity-Related Malignant Neoplasm 2Neoplasms by Site 2Neoplasms by Histologic Type 2Keratosis, Actinic 2Carcinoma, Non-Small-Cell Lung 2Venentoclax 1Uterine Neoplasms 1Uterine Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Tongue Neoplasms 1Syndrome 1Stomach Ulcer 1Small Cell Lung Carcinoma 1Secondary Malignant Neoplasm of Liver 1Salivary Gland Neoplasms 1Salivary Gland Malignant Neoplasms 1Rectal Malignant Neoplasms 1Preleukemia 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Non-Malignant Neoplasm × Other neoplasm × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡